|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����ʮ���� |
|
����(�ڴ�)�����Ե������� |
|
���̲���ص�Kaposi���� |
| ��������������� | |
|
���������� |
|
�������У |
| PubMed | |
|
Article by ���������� |
|
Article by �������У |
��������ҩ��������ʮ����
����������1, �������У2
1. �й�ҽѧ��ѧԺƤ�����о���;
2. �й�Э��ҽ�ƴ�ѧƤ�����о���
����ʮ������2000�������״����еĻ�ѧ�ṹ�����û���ȫ�µĹ�������ҩ��,��Ҫͨ�����Ų�����Ĥ������ϸ��Ĥ���ں϶��������á�����ʳƷ��ҩ��������10%����ʮ���������������(�ڴ�)�����Ե������������,��ҩ�ڰ��̲���ص�Kaposi������������������DZ�ڵ�Ӧ�ü�ֵ��
1. �й�ҽѧ��ѧԺƤ�����о���;
2. �й�Э��ҽ�ƴ�ѧƤ�����о���
1. �й�ҽѧ��ѧԺƤ�����о���;
2. �й�Э��ҽ�ƴ�ѧƤ�����о���
[2] Katz DH,Marcelletti JF,Khalil MH,et al.Antiviral activity of 1-do-c osanol,an inhibitor of lipid-enveloped viruses including herpes simplex.Proc Natl Acad Sci USA,1991,88(23):10825-10829.
[3] Scolaro M J,Gunnill LB,Pope LE,et al.The antiviral drug docosanol as atreatment for Kaposi's sarcoma lesions in HIV type 1-infected patients:apilot clinical study.MDS Res Hum Retroviruses,2001.17 (1):35-43.
[4] Pope LE,Marcelletti JF,Katz LR,et al.The anti-herpes simplex virus ac tivity of n-docosanol includes inhibition of the viral entry process.Antiviral Res,1998,40:85-94.
[5] Pope LE,Macelletti JF,Katz LR,et al.Anti-herpes simplex virus activity ofn-docosanol correlates with intracellular metabolic conversion of the drug.J Lipid Res,1996,37(10):2167-2178.
[6] Fuller AO,Spear PG.Anti-glycoprotein D antibodies that permit adsorptionbut block infection by herpes simplex virus I prevent virion-cell fusion atthe cell surface.Proc Natl Acad Sci USA,1987,84(15):5454-5458.
[7] Montgomery RI,Warner MS,Lum BJ,et al.Herpes simplex virus-I entry Zinto cells mediated by a novel member of the TNF/NGF receptor family.Cell,1996,87(3):427-436.
[8] Roos DS,Choppin PW.Biochemical studies on cell fusion.��.Control oflfusion response by lipid alteration.J Cell Biol,1985.101 (4):1591-1598.
[9] Alrabiah FA,Sacks SL.New antiherpesvirus agents:Their targets and ther-apeutic potential.Drugs,1996,52(1):17-32.
[10] Habbema L,De Boulle K,Roders GA,et al.n-Docosanol 10% cream in thetreatment of recurrent herpes labialis:a randomised,double-blind,placebo-controlled study.Acta Derm Venereol(Stockh),1996,76(6):479-481.
[11] Sacks SL,Thisted RA,Jones TM,et al.Clinical efficacy of topical do-cosgnol 10% cream for herpes simplex labialis:A multicenter,randomized,placebo-controlled trial.J Am Acad Dermatol,2001,45(2):222-230.
[12] Mihalcea AM,Smith DL,Monini P,et al.Treatment update for AIDS-relat-ed Kaposi's sarcoma.AIDS,1999,13(Suppl A):S215-S225.
[13] Khalil MH,Marcelletti JF,Katz LR,et al.Topical applicatnon of docosanol-or stearic acid-containing creams reduces severity of phenol burn wounds inmice.Contact Dermatitis,2000,43(2):79-81.
[14] Safrin S Assaykeen T,Follansbee S,et al.Foscamet therapy for acyclovir resistant mucocutaneous herpes simplex virus inlection in 26 AIDS pa-tients:Preliminary data.J Infect Dis,1990,161 (6):1078-1084.